BLACKSTONE INC (BX) Q3 2026 Earnings Call Transcript

Blackstone Inc (BX) reported Q3 2026 GAAP net income of $1.3B, distributable earnings of $1.7B ($1.32/share), and declared a $1.12/share dividend. CEO Steve Schwarzman highlighted strong inflows ($63B in Q3, $270B in 12 months) and outperforming flagship strategies, despite market volatility. The company emphasized its AI-driven investment opportunities and partnerships, including with Google, Anthropic, and NVIDIA.

Original reporting
Published Oct 22, 2026, 2:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BX
Neutral
high confidence
Mentioned
$BX
Relevance
9/10
AlphAI data visualization · based on news.alphastreet.com
Decision brief

The 30-second read

$BXNeutralHigh
01

Why it matters

The earnings release offers fresh data on profitability, cash generation, and dividend policy, giving traders a basis to adjust positions.

02

Market read

Blackstone's sizable earnings and dividend announcement are material for the alternative‑asset sector and may influence related AI‑infrastructure and energy stocks.

03

What to watch

The $63 B quarterly inflows and $270 B 12‑month fundraising highlight continued investor appetite, which may support the stock despite macro headwinds.

Relevance 9/10Novelty 9/10Timing: post‑market today

Background

Blackstone Inc (BX) held its Q3 2026 earnings call, providing the first public disclosure of quarterly results and dividend.

Company-level read

Ticker impact

$BXNeutralHigh confidence
Context

Q3 2026 GAAP net income of $1.3 B, distributable earnings $1.7 B and a $1.12 per share dividend were disclosed in the earnings call.

Expected impact

likely modest pressure as investors price in higher yields despite solid earnings and dividend.

Evidence & confidence

The fresh earnings numbers and dividend announcement provide a concrete catalyst; however, Blackstone highlighted a challenging macro environment that could temper the rally.

Market effects

AI infrastructure spending and energy assets are highlighted as growth drivers, potentially boosting related tech and energy stocks.

U.S. markets may see modest volatility as Blackstone's earnings reflect broader concerns over rising yields and geopolitical risks.

The earnings underscore the impact of global bond‑yield spikes on alternative‑asset managers worldwide.

Counterpoint

Despite strong earnings, the elevated cost of capital and AI‑related capital intensity could pressure Blackstone's valuation longer term.

Key entities

  • Steve Schwarzman

    Chairman and CEO of Blackstone, provided commentary on macro environment.

  • Jon Gray

    President and COO, contributed to earnings discussion.

Related articles

$BXHigh

Blackstone's 16% Stake In IIFL Finance To Strengthen Capital Base

Blackstone Inc. plans to acquire a 16% stake in IIFL Finance, investing Rs 5,000 crore to boost its capital base. Fitch Ratings expects this to double IIFL Finance's Tier 1 capital ratio to 25.7% by September 2026, enhancing its funding flexibility and supporting growth plans. The transaction is not expected to immediately impact IIFL Finance's ratings or business model, which focuses on secured lending.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.